• Home
  • Corporate
    • About us
    • Team
  • Science
    • Research strategy
    • BPH
    • Fexapotide for BPH
    • Pipeline
    • Scientific Publications
  • Products
    • Fexapotide Triflutate
    • NicAlert®
    • TobacAlert®
  • Investors
    • Overview
    • Company Presentation
    • Stock Info
    • Email Alerts
    • Corporate Governance
    • SEC Filings
    • Annual Reports
  • News
    • Press Releases
    • Upcoming Events
  • Contact
nymox Logo
  • Home
  • Corporate
    • About us
    • Team
  • Science
    • Research strategy
    • BPH
    • Fexapotide for BPH
    • Pipeline
    • Scientific Publications
  • Products
    • Fexapotide Triflutate
    • NicAlert®
    • TobacAlert®
  • Investors
    • Overview
    • Company Presentation
    • Stock Info
    • Email Alerts
    • Corporate Governance
    • SEC Filings
    • Annual Reports
  • News
    • Press Releases
    • Upcoming Events
  • Contact
Navigation

Scientific Publications

Fexapotide triflutate: results of long‑term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.
Shore et al. World Journal of Urology. 2018;36(5):801-9.


Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia.
Shore et al. Therapeutic Advances in Urology. 2019;11:1-16.

Download Publication


  • Disclaimer
  • Privacy Policy
  • Contact
Glossary